Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Solution To Chemistry Riddle Has Implications For Drug Development

By Trinity College Dublin | July 6, 2018

Scientists have solved a decades-old chemistry riddle by developing new tools for a synthetic (man-made) molecule – cubane – that is widely used in the pharma industry. By circumventing the inherent reactivity of this molecule, they have opened up a new world of possibilities as cubane derivatives have a plethora of applications in drug development, materials science, and molecular engineering.

Cubane molecules consist of eight carbon atoms arranged at the corners of a perfect cube. Yet despite the simplicity of the shape, modern chemistry has, until now, had a very tough time handling its unique reactivity.

Although it is absent in nature, cubane mimics the effect of the very abundant benzene-motif, by improving the effects of drugs and/or reducing their side effects. Despite this ability, which makes it of potential use in medicinal drug development, or as a rigid, isolating linker that can join and organise different molecules in materials science, the range of applications was greatly limited as more complex systems were out of bounds.

However, this lack of a synthetic handle has now been tackled by a team from Trinity College Dublin’s School of Chemistry. Their discovery has recently been published in the international journal Chemistry – A European Journal, in which it features as a VIP paper and on the journal front cover.

A team of six researchers under the supervision of Professor of Organic Chemistry at Trinity, Mathias O. Senge, discovered how to circumvent the inherent reactivity of the cubane core. Senior Research Fellow, Dr Bernhard, and the other team members essentially filled the empty cubane toolbox, which allowed them to establish new connections and craft important residues onto the cubane scaffold. As a result, they have opened new vistas in drug development and material sciences.

Professor Senge said: “I often challenge my students to think outside the box so I was really surprised when they pitched me the idea of literally making a box! However, it is the apparent simplicity of the cubane core that really underlies the impact of the present accomplishment.”

“We have a structurally unique building block which has been neglected by the majority of synthetic chemists up to now precisely because of how difficult this cube is to work with. However, with great risk comes great reward. I am delighted with our present success and intrigued about the avenues it will open in fields ranging from new drug discovery to 21st century computer chip generation!”

“Science has known for a long time that cubanes held great potential for medicinal drug development, and for shifting the barriers of materials science, and that much of that potential was still to be unlocked. To perform that lock-picking, we just needed the right tools, and having found them, we are really excited for what the future holds.”

“The results from this long-term, fundamental research project will have significant benefits in the years to come as we can now prepare a greater variety of tailored compounds. We are very grateful to have received continuous long-term funding from Science Foundation Ireland to support this work, without which we would not have made this important discovery.”

(Source: Trinity College Dublin)


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE